Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing) Advani, R. H., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Christian, B. A., Ansell, S. M., Moskowitz, C. H., Fenton, K., Ogden, C., Taft, D., Zak, D. E., Sacchi, M., Galderisi, F., Herrera, A. F. AMER SOC HEMATOLOGY. 2018

View details for DOI 10.1182/blood-2018-99-110002

View details for Web of Science ID 000454837605012